|
GSK PLC - west London-based pharmaceutical firm formerly known as GlaxoSmithKline - Makes further appointments to the designate board of Haleon, the independent company to be formed following the demerger of its Consumer Healthcare business. GSK's nominations for independent non-executive directors are Asmita Dubey, chief digital & marketing officer at L'Oreal SA who built the company's first joint businesses with Alibaba Group Holding Ltd and Tencent Holdings Ltd, and Marie-Anne Aymerich who led the worldwide Oral Care category at Unilever PLC.
Pfizer Inc, who owns 32% of the Haleon joint venture, nominates Bryan Supran as non-executive director, who has served as senior vice president & deputy general counsel at Pfizer since 2015.
‘Together they bring a strong understanding of the global consumer sector, as well as relevant innovation and Asia experience. These appointments now complete the Designate Board ahead of the demerger of Haleon from GSK,’ says Haleon Chair Designate Dave Lewis.
The demerger is still on track for July of 2022, GSK confirms.
Current stock price: 1,722.20 pence
12-month change: up 29%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
